Hamid Reza Jamshidi

List of Publications by Year
in descending order

46 papers	1,209 citations	566801 15 h-index	395343 33 g-index
48 all docs	48 docs citations	48 times ranked	2581 citing authors

#	Article	IF	Citations
1	Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behvarz) Tj ETQq1 1 0.784314 rgBT /O	6.3	184
2	Decomposing socioeconomic inequality in infant mortality in Iran. International Journal of Epidemiology, 2006, 35, 1211-1219.	0.9	170
3	National action plan for non-communicable diseases prevention and control in Iran; a response to emerging epidemic. Journal of Diabetes and Metabolic Disorders, 2017, 16, 3.	0.8	143
4	Iran in transition. Lancet, The, 2019, 393, 1984-2005.	6.3	131
5	NASBOD 2013: design, definitions, and metrics. Archives of Iranian Medicine, 2014, 17, 7-15.	0.2	62
6	National and Subnational Patterns of Cause of Death in Iran 1990-2015: Applied Methods. Archives of Iranian Medicine, 2017, 20, 2-11.	0.2	56
7	Measuring Iran's success in achieving Millennium Development Goal 4: a systematic analysis of under-5 mortality at national and subnational levels from 1990 to 2015. The Lancet Global Health, 2017, 5, e537-e544.	2.9	49
8	Safety and potency of BIV1â€CovIran inactivated vaccine candidate for SARSâ€CoVâ€2: A preclinical study. Reviews in Medical Virology, 2022, 32, e2305.	3.9	40
9	Umbelliprenin shows antitumor, antiangiogenesis, antimetastatic, antiâ€inflammatory, and immunostimulatory activities in 4T1 tumorâ€bearing Balb/c mice. Journal of Cellular Physiology, 2018, 233, 8908-8918.	2.0	28
10	Burden of Drug and Alcohol Use Disorders in Iran: findings from the Global Burden of Disease Study 2010. Archives of Iranian Medicine, 2015, 18, 480-5.	0.2	26
11	"We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran. Health Research Policy and Systems, 2010, 8, 9.	1.1	24
12	Diffusion of magnetic resonance imaging in Iran. International Journal of Technology Assessment in Health Care, 2007, 23, 278-285.	0.2	21
13	National and sub-national prevalence, trend, and burden of metabolic risk factors (MRFs) in Iran: 1990 - 2013, study protocol. Archives of Iranian Medicine, 2014, 17, 54-61.	0.2	21
14	National and sub-national burden of breast cancer in Iran; 1990-2013. Archives of Iranian Medicine, 2014, 17, 794-9.	0.2	18
15	Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran. Iranian Journal of Pharmaceutical Research, 2014, 13, 225-34.	0.3	17
16	Impact of rural family physician program on child mortality rates in Iran: a time-series study. Population Health Metrics, 2017, 15, 21.	1.3	16
17	Insulin pen use and diabetes treatment goals: A study from Iran STEPS 2016 survey. PLoS ONE, 2019, 14, e0221462.	1.1	15
18	Red flags of poor prognosis in pediatric cases of COVID-19: the first 6610 hospitalized children in Iran. BMC Pediatrics, 2021, 21, 563.	0.7	15

#	Article	IF	Citations
19	Tobacco Smoking Status and the Contribution to Burden of Diseases in Iran, 1990-2010: findings from the Global Burden of Disease Study 2010. Archives of Iranian Medicine, 2015, 18, 493-501.	0.2	15
20	Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells. Iranian Red Crescent Medical Journal, 2016, 18, e35167.	0.5	14
21	How is magnetic resonance imaging used in Iran?. International Journal of Technology Assessment in Health Care, 2008, 24, 452-458.	0.2	13
22	Evaluating cytotoxic effect of nanoliposomes encapsulated with umbelliprenin on 4T1 cell line. In Vitro Cellular and Developmental Biology - Animal, 2017, 53, 7-11.	0.7	12
23	A Report on Statistics of an Online Self-screening Platform for COVID-19 and Its Effectiveness in Iran. International Journal of Health Policy and Management, 2021, , .	0.5	12
24	National and sub-national burden of chronic diseases attributable to lifestyle risk factors in Iran 1990 - 2013; study protocol. Archives of Iranian Medicine, 2014, 17, 146-58.	0.2	12
25	Proactive agenda setting in creation and approval of national action plan for prevention and control of non-communicable diseases in Iran: The use of multiple streams model. Journal of Diabetes and Metabolic Disorders, 0, , 1.	0.8	11
26	Scientometric Study on Non-communicable Diseases in Iran: A Review Article. Iranian Journal of Public Health, 2018, 47, 936-943.	0.3	9
27	National and sub-national trend and burden of injuries in Iran, 1990 - 2013: a study protocol. Archives of Iranian Medicine, 2014, 17, 138-45.	0.2	9
28	Diffusion of interferon beta in Iran and its utilization in Tehran. Pharmacoepidemiology and Drug Safety, 2008, 17, 934-941.	0.9	8
29	Assessment of BIV1-CovIran inactivated vaccineâ€"elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern. Clinical Microbiology and Infection, 2022, 28, 882.e1-882.e7.	2.8	7
30	Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis. PLoS ONE, 2019, 14, e0198449.	1.1	6
31	The Most Prevalent Causes of Deaths, DALYs, and Geriatric Syndromes in Iranian Elderly People Between 1990 and 2010: findings from the Global Burden of Disease study 2010. Archives of Iranian Medicine, 2015, 18, 462-79.	0.2	6
32	Budget impact analysis of conversion from cyclosporine to sirolimus as immunosuppressive medication in renal transplantation therapy. ClinicoEconomics and Outcomes Research, 2013, 5, 545.	0.7	5
33	Burden of Hepatitis C in Iran Between 1990 and 2010: findings from the Global Burden of Disease Study 2010. Archives of Iranian Medicine, 2015, 18, 508-14.	0.2	5
34	Costs of Treatment after Renal Transplantation: Is it Worth to Pay More?. Iranian Journal of Pharmaceutical Research, 2014, 13, 271-8.	0.3	4
35	Burden of Cancers in Iran from 1990 to 2010: findings from the Global Burden of Disease study 2010. Archives of Iranian Medicine, 2015, 18, 629-37.	0.2	4
36	"Budget impact analyses": a practical policy making tool for drug reimbursement decisions. Iranian Journal of Pharmaceutical Research, 2014, 13, 1105-9.	0.3	3

#	Article	IF	Citations
37	Using drug sales data to evaluate the epidemiology of cardiometabolic risk factors and their inequality: an ecological study on atorvastatin and total cholesterol in Iran. Medical Journal of the Islamic Republic of Iran, 2015, 29, 260.	0.9	3
38	An Approach Towards Reducing Road Traffic Injuries and Improving Public Health Through Big Data Telematics: A Randomised Controlled Trial Protocol. Archives of Iranian Medicine, 2018, 21, 495-501.	0.2	3
39	National and sub-national prevalence, trend, and burden of end stage renal diseases (ESRD) in Iran 1990-2013; the study protocol. Archives of Iranian Medicine, 2014, 17, 800-3.	0.2	3
40	Birth seasonality in rural areas of Iran, analysis of 5,536,262 births from 1992 to 2007. Annals of Epidemiology, 2016, 26, 846-852.e3.	0.9	2
41	A pilot study using financial transactions' spatial information to define high-risk neighborhoods and distribution pattern of COVID-19. Digital Health, 2022, 8, 205520762210762.	0.9	2
42	Wealth-related Inequality in Utilization of Antihypertensive Medicines in Iran: an Ecological Study on Population Level Data. Archives of Iranian Medicine, 2016, 19, 116-22.	0.2	1
43	Combining government, non-pharmaceutical interventions and vaccination in optimal control COVID-19. International Journal of Healthcare Management, 2023, 16, 61-69.	1.2	1
44	Level and trend of total plasma cholesterol in national and subnational of Iran: a systematic review and age-spatio-temporal analysis from 1990 to 2016. Journal of Diabetes and Metabolic Disorders, 2022, 21, 1301-1315.	0.8	1
45	Umbelliprenin efficiently induces complete pathologic response in 4T1 Tumor-bearing Balb/c Mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-28.	0.0	0
46	Correction: An Approach Towards Reducing Road Traffic Injuries and Improving Public Health Through Big Data Telematics: A Randomised Controlled Trial Protocol. Archives of Iranian Medicine, 2022, 25, 76-76.	0.2	0